Quick Answer
Theriva Biologics, Inc. reported R&D Expense of $8.60 million for fiscal year 2025.
Theriva Biologics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $8.60M | -28.5% |
| 2024 | $12.03M | -15.9% |
| 2023 | $14.31M | +22.1% |
| 2022 | $11.72M | +50.3% |
| 2021 | $7.80M | +52.0% |
| 2020 | $5.13M | -53.7% |
| 2019 | $11.08M | -6.4% |
| 2018 | $11.84M | +5881.8% |
| 2018 | $198.0K | -98.9% |
| 2017 | $18.78M | -35.5% |
| 2016 | $29.11M | -11.5% |
| 2015 | $32.91M | +127.1% |
| 2014 | $14.49M | +122.7% |
| 2013 | $6.51M | -47.0% |
| 2012 | $12.29M | +267.9% |
| 2011 | $3.34M | +111.4% |
| 2010 | $1.58M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $2.55M | -6.7% | +30.6% |
| June 30, 2025 | $1.95M | -33.9% | -34.2% |
| March 31, 2025 | $2.97M | -14.2% | +8.6% |
| September 30, 2024 | $2.73M | -31.8% | -7.4% |
| June 30, 2024 | $2.95M | -5.7% | -14.6% |
| March 31, 2024 | $3.46M | +16.2% | -13.7% |
| September 30, 2023 | $4.01M | +55.9% | +27.9% |
| June 30, 2023 | $3.13M | -10.1% | +5.2% |
- Theriva Biologics, Inc. showed a decrease of -28.5% in R&D Expense compared to the prior fiscal year.
- Over the 2010–2025 period, Theriva Biologics, Inc.’s r&d expense has grown by 444.6% (from $1.58 million to $8.60 million).
- The most recent figure is from Theriva Biologics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: